Han Li, Ph.D., MBA,
SVP, Eureka Therapeutics, Inc.
Dr. Li is a biopharmaceutical professional with over 15 years of experience in biotech, pharmaceuticals and healthcare investment. Han started his career at Genentech in 1997 as a research scientist in drug discovery and is a lead inventor of three international patents on novel cytokines. In 2002, he joined Morgan Stanley Investment Bank as an equity research analyst covering biotech industry and companies. In subsequent years, he took leading biotech analyst role as Director, Vice President, Senior Vice President at Suntrust Robinson Humphrey and Stanford Financial Group. He was top rated by the StarMine Analyst Ranking for earnings accuracy and stock recommendation of companies under coverage. Han joined Bayer Pharmaceuticals in 2010 and currently works at Strategic Marketing, focusing on portfolio management and oncology commercial development. In the past six years, he has been actively involved commercial launches of oncology drugs: Stivarga and Xofigo , and various BDL activities (including Algeta Acquisition). Han holds a Ph.D. degree in Pharmacology from Boston University School of Medicine and an M.B.A. degree from University of California at Los Angeles.